

Nizoral^{TRADEMARK}

(ketoconazole) tablets

over 5 million prescriptions world-wide.

Oral medication in antifungal therapy:



Doctors and patients around the world are discovering the modern simplicity of Nizoral oral therapy. Common but often problematic fungal infections can now be treated effectively and elegantly.

Typically, in *Candida* vaginitis, 2 oral tablets once daily for 5 days is all it takes today to effectively cure the problem.




JANSSEN
PHARMACEUTICA

the drug discovery company

Prescribing Information

Presentation: white, flat, half scored uncoated tablets marked "Janssen" on one side and K/200 on the reverse. Each tablet contains 200 mg ketoconazole. **Uses:** Nizoral is an orally active antimycotic for the treatment in adults of vaginal candidosis, superficial and systemic mycoses including dermatophyte and yeast infections of the skin, hair and nails, yeast infections of the mouth and G.I. tract. Also maintenance treatment of systemic mycoses and chronic mucocutaneous candidosis and prophylaxis in "at risk" patients. In children: systemic mycoses and severe local infections where previous topical treatment has failed. **Side-effects, precautions, contra-indications:** contra-indicated in pregnancy. For maximal absorption Nizoral should be taken with meals. The use of agents which reduce gastric acidity (anti-cholinergic drugs, antacids, H₂-blockers) should be avoided and, if indicated, such drugs should be taken not less than two hours after Nizoral. Nausea, skin rash, headache and pruritus may occasionally be observed. Alterations in liver function tests have occurred in patients on ketoconazole, these changes may be transient. Cases of hepatitis have been reported with an incidence of about 1 per 10,000 patients. Some of these may represent an idiosyncratic adverse reaction to the drug. This should be borne in mind in patients on long-term therapy. If a patient develops jaundice or any symptoms suggestive of hepatitis, treatment with ketoconazole should be stopped. Mild asymptomatic increases of liver enzyme levels, on the other hand, do not necessitate discontinuation of the treatment. Ketoconazole, when given together with cyclosporin A results in increased blood levels of cyclosporin A. It is important that blood levels of cyclosporin A are monitored if the two drugs are given concomitantly. Ketoconazole 200 mg once daily produces a transient decrease in plasma levels of testosterone. During long-term therapy at this dose, testosterone levels are usually not significantly different from controls. In rare instances gynecomastia has been reported.

APPROPRIATE TECHNOLOGY



ARTICLES FROM THE BRITISH MEDICAL JOURNAL

APPROPRIATE TECHNOLOGY

Many of the difficulties of Third World medicine – the effects of poverty, starvation, overpopulation, and political unrest – are beyond the individual doctor's control; but what the western trained doctor practising in the developing world can and must do is to adapt his practice to compensate for the absence of sophisticated equipment, trained staff, and expensive drugs. Written by doctors and technicians with first hand experience of the problems, *Appropriate Technology* is a guide to the sensible choice and use of resources.

The British Medical Journal has subsidised this title to make this information widely available at as low a cost as possible.

Price: Inland £3.50; Overseas £5.00/USA\$8.00
(Inland £3.00; Overseas £4.50/USA\$7.00
to BMA members)
Despatched by air overseas

Payment must be enclosed with order

BOOKS FROM THE BMJ

Order from
The Publishing Manager, British Medical Journal,
BMA House, Tavistock Square, London WC1H 9JR
or any leading bookseller

International Medical Course

Interventional radiology

7 - 13 December 1986 in London

This seminar is being organized by the British Council in co-operation with the departments of Radiology at King's College Hospital and Northwick Park Hospital in London.

The aim is to review the basic principles of interventional procedures in radiology, to discuss recent advances and current concepts in these techniques including the details of the procedures practised in Britain.

It is expected that those attending will have had some experience of interventional radiology in addition to being established diagnostic radiologists of some years' standing.

The Directors of Studies will be **Dr Heather B Nunnerley** of King's College Hospital and **Dr R A Wilkins** of Northwick Park Hospital.

The seminar is designed for diagnostic radiologists interested in extending their knowledge of interventional radiology.

There are vacancies for 35 participants. Fee £520 Residential, £340 Non-residential.

The working sessions will take place at an hotel in Central London where resident participants will also be accommodated.

Further information and application forms are available from British Council Representatives overseas or from Courses Department, The British Council, 65 Davies Street, London W1V 2AA.

The
British
Council

EPIDEMIOLOGY FOR THE UNINITIATED

GEOFFREY ROSE, D J P BARKER SECOND EDITION

Get a working knowledge of epidemiology

No one would expect to understand a disease without knowledge of its clinical findings and pathology, but a surprising number of doctors remain ignorant of another important aspect – the study of disease in relation to populations. Epidemiology has its own techniques of data collection and interpretation and its necessary jargon of technical terms, and in *Epidemiology for the Uninitiated* Professors Geoffrey Rose and David Barker guide the novice expertly through the theory and practical pitfalls. The second edition of this popular *BMJ* handbook has been revised to include further details of epidemiological methods and some of their more dramatic applications, such as the investigations on the Spanish cooking oil epidemic, and AIDS.

Price: Inland £3.95; Abroad £5.50; USA \$8.50
BMA members; Inland £3.45; Abroad £5.00; USA \$7.50

(Please quote membership number)
Prices include postage, by air abroad.
Payment must be enclosed with order.

BOOKS FROM THE BMJ

Order from
The Publishing Manager, British Medical Journal,
BMA House, Tavistock Square, London WC1H 9JR
or any leading bookseller

AUGMENTIN

clavulanate-potentiated amoxycillin

A MAJOR DEVELOPMENT IN ANTIBIOTIC THERAPY

In recent years, the treatment of infection has been complicated by the increasing prevalence of β -lactamase producing strains of bacteria. β -lactamase destroys many oral cephalosporins and penicillins,^{1,2} resulting in treatment failure.

AUGMENTIN is the first antibiotic to utilise Beecham's discovery of the powerful β -lactamase inhibitor, clavulanic acid. This neutralises the bacterial defence, bringing more strains and species within the scope of oral therapy.

● **AUGMENTIN – Broader in spectrum**
than oral cephalosporins, co-trimoxazole, ampicillin, tetracycline or erythromycin.

● **AUGMENTIN – Outstanding success**
against today's infections.

| Adult infections | No. of patients assessed | Clinically cured/improved | Clinical success |
|--------------------------------------|--------------------------|---------------------------|------------------|
| Upper respiratory tract ³ | 146 | 141 | 97% |
| Lower respiratory tract ³ | 98 | 89 | 91% |
| Urinary tract ³ | 175 | 167 | 95% |
| Skin & soft tissue ^{3,4} | 81 | 75 | 93% |

| Paediatric infections | No. of patients assessed | Clinically cured/improved | Clinical success |
|--|--------------------------|---------------------------|------------------|
| Upper respiratory tract ^{5,6} | 70 | 70 | 100% |
| Lower respiratory tract ⁷ | 28 | 27 | 96% |
| Urinary tract ^{6,7,8} | 61 | 57 | 93% |

PRESCRIBING INFORMATION

INDICATIONS: Chest, ear, nose, throat, genito-urinary, skin and soft tissue infections including those caused by β -lactamase producing organisms.

DOSAGE: Adults and children over 12 years one AUGMENTIN tablet (375mg) three times daily. Children 7-12 years 10ml AUGMENTIN syrup (312mg) three times daily. Children 2-7 years 5ml AUGMENTIN syrup (156mg) three times daily. Children 9 months – 2 years 2.5ml AUGMENTIN syrup (78mg) three times daily. In severe infections these dosages may be doubled. Treatment should not be extended beyond 14 days without review.

CONTRA-INDICATION: Penicillin hypersensitivity. **PRECAUTIONS:** Safety in human pregnancy is yet to be established. Oral dosage need not be reduced in patients with renal impairment unless dialysis is required. **SIDE-EFFECTS:** Uncommon, mainly mild and transitory, eg diarrhoea, indigestion,

nausea, vomiting, candidiasis, urticarial and morbilliform rashes. If gastrointestinal side-effects do occur they may be reduced by taking AUGMENTIN at the start of meals. **PRESENTATIONS:** 375mg AUGMENTIN tablets each containing 250mg amoxycillin (1) and 125mg Clavulanic acid. (2) 156.25mg AUGMENTIN syrup. Powder for preparing fruit flavoured syrup. When dispensed each 5ml contains 125mg amoxycillin (1) and 31.25mg clavulanic acid. (2) (1) as the trihydrate, (2) as the potassium salt. Not all presentations are available in every country.



Further information is available from:
Beecham Research Laboratories
Brentford, Middlesex, England.
AUGMENTIN and the BRL logo are trademarks.

References 1. Proc. Int. Symp. on AUGMENTIN, Excerpta Med. (1980), ICS 544, 173. 2. Excerpta Med. (1980), ICS 544, 19. 3. Excerpta Med. (1980), ICS 544, 187. 4. Scot. Med. J., (1982), 27, S35. 5. Proc. Europ. Symp. on AUGMENTIN, Excerpta Med. (1982), CCP4, 341. 6. Excerpta Med. (1982), CCP4, 347. 7. Excerpta Med. (1982), CCP4, 325. 8. Excerpta Med. (1982), CCP4, 334.

